[HTML][HTML] Future therapeutics in Alzheimer's disease: development status of BACE inhibitors
G Evin - BioDrugs, 2016 - Springer
Alzheimer's disease (AD) is the primary cause of dementia in the elderly. It remains
incurable and poses a huge socio-economic challenge for developed countries with an …
incurable and poses a huge socio-economic challenge for developed countries with an …
Discovery of the 3-imino-1, 2, 4-thiadiazinane 1, 1-dioxide derivative verubecestat (MK-8931)–a β-site amyloid precursor protein cleaving enzyme 1 inhibitor for the …
JD Scott, SW Li, APJ Brunskill, X Chen, K Cox… - 2016 - ACS Publications
Verubecestat 3 (MK-8931), a diaryl amide-substituted 3-imino-1, 2, 4-thiadiazinane 1, 1-
dioxide derivative, is a high-affinity β-site amyloid precursor protein cleaving enzyme 1 …
dioxide derivative, is a high-affinity β-site amyloid precursor protein cleaving enzyme 1 …
Beyond immunotherapy: new approaches for disease modifying treatments for early Alzheimer's disease
Introduction: Current pharmacological recommendations for the treatment of Alzheimer's
disease (AD) include the cholinesterase inhibitors and the N-methyl-D-aspartate antagonist …
disease (AD) include the cholinesterase inhibitors and the N-methyl-D-aspartate antagonist …
Alzheimer's disease: where next for anti-amyloid therapies?
J Hardy, B De Strooper - Brain, 2017 - academic.oup.com
The recent failures of the solanezumab Expedition 3 and the verubecestat phase II/III trials to
significantly slow disease progression in mild or mild-to-moderate Alzheimer's disease are …
significantly slow disease progression in mild or mild-to-moderate Alzheimer's disease are …